Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
BMC Microbiol
2023 Mar 16;231:74. doi: 10.1186/s12866-023-02801-4.
Show Gene links
Show Anatomy links
Gut microbiota characteristics of Mongolian and Han populations in anti-tuberculosis drug-induced liver injury: a population-based case-control study.
Hao J
,
Li Y
,
Yu Y
,
Zheng L
,
Feng F
.
Abstract
BACKGROUND: The pathogenesis of anti-tuberculosis (TB) drug-induced liver injury (ADLI) is complicated and remains unclear. We aimed to analyse the relationship between the characteristics of gut microbiota and ADLI in Mongolian and Han patients with pulmonary TB and identify the most notable bacteria related to the occurrence of liver injury in those populations.
METHODS: Patients with concurrent liver injury (LI) and no liver injury (ULI) before receiving first-line anti-TB drug treatment (T1) from the Han population in Tangshan and the Mongolian population in Inner Mongolia were selected as research subjects. At the time of liver injury (T2), stool samples were measured by bacterial 16S rRNA gene high-throughput sequencing to analyse and compare the differences in the gut microbiota of the LI and ULI Mongolian and Han patients at T1 and T2 and identify the differences between those patients.
RESULTS: A total of 45 Mongolian and 37 Han patients were enrolled in our study. A dynamic comparison from T1 to T2 showed that the microbiota of the LI and ULI groups changed significantly from T1 to T2 in both the Mongolian and Han populations. However, there were commonalities and personality changes in the microbiota of the two ethnic groups.
CONCLUSION: Differences in gut microbes in ADLI were found among the Han and Mongolian patients in our study. Ekmania and Stenotrophomonas were related to the occurrence of ADLI in Mongolian patients, while Ekmania and Ruminococcus__gnavus_group were related to the occurrence of ADLI in the Han population.
Alcazar,
Gut microbiota is associated with metabolic health in children with obesity.
2022, Pubmed
Alcazar,
Gut microbiota is associated with metabolic health in children with obesity.
2022,
Pubmed
Cheng,
Gut microbiota, bile acids, and nature compounds.
2022,
Pubmed
Federici,
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.
2022,
Pubmed
Gaulke,
The influence of ethnicity and geography on human gut microbiome composition.
2018,
Pubmed
Ghosh,
Adjusting for age improves identification of gut microbiome alterations in multiple diseases.
2020,
Pubmed
Guedj,
Gut microbiota shape 'inflamm-ageing' cytokines and account for age-dependent decline in DNA damage repair.
2020,
Pubmed
Hu,
Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.
2019,
Pubmed
Jang,
Evidence for interplay among antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in mice.
2018,
Pubmed
Jia,
Endocrine organs of cardiovascular diseases: Gut microbiota.
2019,
Pubmed
Jin,
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
2019,
Pubmed
Kim,
Sequence meets function-microbiota and cardiovascular disease.
2022,
Pubmed
Liang,
Metformin attenuated sepsis-related liver injury by modulating gut microbiota.
2022,
Pubmed
Litichevskiy,
The Oscillating Gut Microbiome and Its Effects on Host Circadian Biology.
2022,
Pubmed
Moeller,
Dispersal limitation promotes the diversification of the mammalian gut microbiota.
2017,
Pubmed
Nam,
Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing.
2011,
Pubmed
Namasivayam,
Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
2017,
Pubmed
Pareek,
Comparison of Japanese and Indian intestinal microbiota shows diet-dependent interaction between bacteria and fungi.
2019,
Pubmed
Peters,
US nativity and dietary acculturation impact the gut microbiome in a diverse US population.
2020,
Pubmed
Porter,
The microbiome in prostate inflammation and prostate cancer.
2018,
Pubmed
Steiner,
Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.
2022,
Pubmed
Tseng,
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
2021,
Pubmed
Vich Vila,
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota.
2020,
Pubmed
Vujkovic-Cvijin,
The systemic anti-microbiota IgG repertoire can identify gut bacteria that translocate across gut barrier surfaces.
2022,
Pubmed
Wan,
Contribution of diet to gut microbiota and related host cardiometabolic health: diet-gut interaction in human health.
2020,
Pubmed
Wang,
Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.
2022,
Pubmed
Wilmanski,
Blood metabolome predicts gut microbiome α-diversity in humans.
2019,
Pubmed
Wilson,
Gut microbiome interactions with drug metabolism, efficacy, and toxicity.
2017,
Pubmed
Xu,
Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China.
2022,
Pubmed
Yang,
[Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms].
2022,
Pubmed
Yu,
Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice.
2019,
Pubmed
Zhang,
[Effects of Short-term Application of Moutai-flavor Vinasse Biochar on Nitrogen Availability and Bacterial Community Structure Diversity in Yellow Soil of Guizhou Province].
2020,
Pubmed
Zhang,
A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities.
2015,
Pubmed
Zhao,
Metformin Mitigates Sepsis-Related Neuroinflammation via Modulating Gut Microbiota and Metabolites.
2022,
Pubmed
Zimmermann,
Separating host and microbiome contributions to drug pharmacokinetics and toxicity.
2019,
Pubmed
de la Cuesta-Zuluaga,
Age- and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults.
2019,
Pubmed
